- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Bruce Sherman: Why Co-pay Accumulator Programs Are an Unlikely Fit for High-Cost Therapies
Co-pay accumulator adjustment programs will probably not be used for high-cost therapies because deductible amounts are trivial compared with their price tags and because these novel treatments are used for small populations, said Bruce Sherman, MD, chief medical officer of the National Alliance of Healthcare Purchaser Coalitions.
Co-pay accumulator adjustment programs will probably not be used for high-cost therapies because deductible amounts are trivial compared with their price tags and because these novel treatments are used for small populations, said Bruce Sherman, MD, chief medical officer of the National Alliance of Healthcare Purchaser Coalitions.
Transcript
As more novel, life-saving therapies with high price tags come to market, what impact will we see on the access and use of these therapies with co-pay accumulator adjustment programs in place?
I think we have to be mindful of the cost of those products in the context of the potential savings from the co-pay accumulator adjustment programs, because the deductible for an individual, even if that deductible were to be entirely accounted for by the cost of the medication, is trivial relative to the acquisition cost of the drug. So that together with the fact that these more expensive therapies are going to be likely provided to a much smaller population in a covered context of health plan enrollment, my sense is those co-pay accumulator adjustment programs probably will not be used in that setting.
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
Best of Managed Care Cast: Top 5 Episodes From the First Half of 2025
July 18th 2025These interviews are the top episodes, by listens, from among the 21 podcast episodes The American Journal of Managed Care® produced over the first half of 2025. Give them all another listen, and perhaps learn something new.
Read More
